ARTLNasdaqPharmaceutical PreparationsFiscal year ends December 31

ARTELO BIOSCIENCES, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q/A on Aug 20, 2026

$2.66−0.04 (-1.48%)

Close on Oct 19, 2026

Market cap: $7.21M
P/E (TTM): –
Dividend yield: –

ARTELO BIOSCIENCES, INC. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2021 2021-08-31	FY 2020 2020-08-31	FY 2019 2019-08-31	FY 2018 2018-08-31	FY 2017 2017-08-31	FY 2016 2016-08-31	FY 2015 2015-08-31	FY 2014 2014-08-31
Cash & Equivalents	0.60	2.34	2.82	6.63	2.14	4.42	0.34	0.57	0.00	0.02	0.01
Short-Term Investments	–	0	7.61	3.44	0	–	–	–	–	–	–
Cash & Short-Term Investments	0.60	2.34	10	10	2.14	4.42	0.34	0.57	0.00	0.02	0.01
Prepaid Expenses & Other	0.10	0.22	0.55	0.25	0.20	0.02	0.04	–	–	–	–
Total Current Assets	0.70	2.56	11	10	2.34	4.44	0.40	0.57	0.00	0.02	0.01
Property, Plant & Equipment	–	–	–	–	0.00	0.00	0.00	–	–	–	–
Accumulated Depreciation	–	–	–	–	0.00	0.00	0.00	–	–	–	–
Long-Term Investments	–	0	7.61	3.44	–	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	0.06	0.10	0.02	0.09	0	–	–	–	–	–	–
Intangible Assets	2.04	2.04	2.04	2.04	2.04	2.04	–	–	–	–	–
Other Long-Term Assets	–	–	–	0.19	–	–	–	–	–	–	–
Total Assets	2.80	4.70	13	13	4.38	6.48	0.40	0.57	0.00	0.02	0.01
Accounts Payable	3.04	1.68	1.24	0.47	0.49	0.35	0.53	0.03	0.01	0.00	–
Accrued Expenses	0.01	0	–	–	–	–	–	–	–	–	–
Current Portion of Leases	0.04	0.04	0.02	0.03	0	–	–	–	–	–	–
Total Current Liabilities	4.04	1.77	1.29	0.53	0.50	1.02	0.53	0.03	0.02	0.00	–
Long-Term Leases	0.03	0.07	0	0.07	–	–	–	–	–	–	–
Operating Lease Liabilities	0.07	0.10	0	0.07	0	–	–	–	–	–	–
Total Liabilities	4.07	1.84	1.29	0.59	0.50	1.02	0.53	0.03	0.02	0.00	0
Preferred Stock	0	0	0	0	0	–	–	–	–	–	–
Common Stock	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.01	0.01	0.01	0.01
Additional Paid-In Capital	62	53	52	29	13	10	2.51	0.83	0.04	0.04	0.02
Retained Earnings	-63	-50	-40	-17	-9.47	-4.81	-2.64	-0.30	-0.06	-0.03	-0.02
Comprehensive Income & Other	-0.27	-0.20	-0.20	0.02	0.06	-0.01	-0.01	0.00	–	–	–
Shareholders' Equity	-1.27	2.86	12	12	3.88	5.46	-0.13	0.54	-0.01	0.02	0.01
Total Equity	-1.27	2.86	12	12	3.88	5.46	-0.13	0.54	-0.01	0.02	0.01
Total Liabilities & Equity	2.80	4.70	13	13	4.38	6.48	0.40	0.57	0.00	0.02	0.01
Shares Outstanding(shares)	0.67	0.57	0.53	0.27	0.83	0.56	0.29	0.24	0.16	0.16	0.13

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -1625.1%

Financial strength

Current ratio: 3.00
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 288.5%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 1.44
Dividend yield: –